Inhibitors of dipeptidyl peptidase IV
AssigneeFerring B.V.
InventorsDavid Michael Evans, Gary Robert William Pitt
Life of this patent
Estimating the term…
Abstract
Compounds according to formula (1), wherein R1 is H or CN, X1 is S, O, SO2 or CH2, X2 is CO, CH2 or a covalent bond, Het is a nitrogen-containing heterocycle and n is 1-5 are new. The compounds of the invention are inhibitors of dipeptidyl peptidase IV. Pharmaceutical compositions of the compounds of the invention, or pharmaceutically acceptable salts thereof, are useful in the treatment of, inter alia, type 2 diabetes. 1
Claims15
1 A compound selected from derivatives of formula 1, tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of -said derivatives;
- tautomers and isomers
- 139
- wherein:
- R1 is either a hydrogen atom or a nitrile group;
- X1 is selected from a sulphur atom, an oxygen atom, a sulphonyl group and a methylene group;
- X2 is a carbonyl group, a methylene group or a covalent bond;
- Het is an aromatic nitrogen-containing heterocycle selected from pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl and benz-fused analogues thereof, all of which may optionally be substituted on one or more carbon atoms, and where the substituents are selected from C1-C6 alkyl, hydroxy, C1-C6 alkyloxy, amino, C1-C6 alkylamino, di(C1-C6 alkyl)amino, fluoro, chloro, bromo, trifluoromethyl, nitro, cyano, carboxy and C1-C6 alkyloxycarbonyl groups;
- and
- n is 1-5.
2 A compound according to claim 1 wherein R1 is a nitrile group.
3 A compound according to claim wherein the stereochemistry of the nitrile group is as shown in formula 2
- 140
4 A compound according to claim 1 or 2 wherein the stereochemistry of the centre adjacent to the primary amine is of the S configuration as, shown in formula 3
- 141
5 A compound according to claim 4 wherein R1 is a nitrile group and the stereochemistry of the nitrile group is as shown in formula 4
- 142
6 A compound according to any preceding claim wherein X1 is selected from a sulphur atom and a methylene group.
7 A compound according to any preceding claim wherein n is 3 or 4.
8 A compound according to any preceding claim selected from:
- (2S)-1-[Nω-(Pyrazinyl-2-carbonyl)-L-ornithinyl]pyrrolidine-2-carbonitrile,
- (2S)-1-[Nω-(Pyrazinyl-2-carbonyl)-L-lysinyl]pyrrolidine-2-carbonitrile,
- (2S)-1-[(2′S)-2′-Amino-4′-(pyrazinyl-2″-carbonylamino)butanoyl]pyrrolidine-2-carbonitrile,
- (4R)-3-[Nω-(Pyrazinyl-2-carbonyl)-L-lysinyl]thiazolidine-4-carbonitrile,
- 1-[Nω-(Pyrazinyl-2-carbonyl)-L-ornithinyl]pyrrolidine,
- 3-[Nω-(2-Chloropyridyl-3-carbonyl)-L-ornithinyl]thiazolidine,
- 1-[Nω-(2-Chloropyridyl-3-carbonyl)-L-ornithinyl]pyrrolidine,
- (2S)-1-[Nω-(2-Chloropyridyl-3-carbonyl)-L-ornithinyl]pyrrolidine-2-carbonitrile,
- 3-[Nω-(Pyrazinyl-2-carbonyl)-L-ornithinyl]thiazolidine,
- 3-[Nω-(5-Cyano-2-pyridyl)-L-lysinyl]thiazolidine,
- (2S)-1-[Nω-(5-Cyano-2-pyridyl)-L-lysinyl]pyrrolidine-2-carbonitrile,
- (2S)-1-[Nω-(5-Trifluoromethyl-2-pyridyl)-L-ornithinyl]pyrrolidine-2-carbonitrile,
- 3-[Nω-(2-Quinolinylmethyl)-L-lysinyl]thiazolidine,
- 3-[Nω-(2-Quinolinylmethyl)-L-ornithinyl]thiazolidine,
- 3-[Nω-(2-Quinoxaloyl)-L-lysinyl]thiazolidine,
- 3-[Nω-(2-Quinoxaloyl)-L-ornithinyl]thiazolidine,
- (2S)-1-[Nω-(2-Quinoxaloyl)-L-ornithinyl]pyrrolidine-2-carbonitrile,
- 3-[Nω-(6-Methylpyrazinyl-2-carbonyl)-L-ornithinyl]thiazolidine,
- 3-[Nω-(Isoquinoline-3-carbonyl)-L-ornithinyl]thiazolidine, and
- 3-[Nω-(6-Trifluoromethylnicotinoyl)-L-ornithinyl]thiazolidine.
9 A pharmaceutical composition for human therapeutic use comprising at least one compound according to any preceding claim.
10 A composition according to claim 9 for the treatment of type 2 diabetes or impaired glucose tolerance.
11 A composition according to claim 9 for the treatment of growth hormone deficiency or polycystic ovary syndrome.
12 A composition according to claim 9 for the treatment of auto-immune or inflammatory disease.
13 The use of a compound according to any of claims 1 to 8 for the preparation of a pharmaceutical composition for the treatment of at least one of type 2 diabetes, impaired glucose tolerance, growth hormone deficiency, polycystic ovary syndrome, and auto-immune and inflammatory diseases.
14 The use of a compound according to any of claims 1 to 8 for the treatment of at least one of type 2 diabetes, impaired glucose tolerance, growth hormone deficiency, polycystic ovary syndrome, and auto-immune and inflammatory diseases.
15 A method of treatment of at least one of type 2 diabetes, impaired glucose tolerance, growth hormone deficiency, polycystic ovary syndrome, and auto-immune and inflammatory diseases, which comprises the administration to a patient in need of such treatment of a therapeutically effective amount of a compound according to any of claims 1 to 8.